Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

Olfactomics Surgery

Financiado

Cerrado

BRINGING SURGERY TO THE 21ST CENTURY REAL TIME TISSUE ANALYSIS DURING CANCER SU...

BRINGING SURGERY TO THE 21ST CENTURY REAL TIME TISSUE ANALYSIS DURING CANCER SURGERY. Improving Patient Safety Quality and Cost Effectiveness Currently, cancer tumor removal operation is based on preoperative imaging and postoperative pathological examination. There is a strong global trend towards more tissue-sparing and minimally invasive surgery. If all cancer is not... ver más

31/12/2022

OLFACTOMICS OY

3M€

Presupuesto del proyecto: 3M€

Líder del proyecto

OLFACTOMICS OY No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 3 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2022-12-31

EIC-SMEInst-2018-2020: SME instrument

I+D

Cerrada hace 7 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

3 Participantes

OLFACTOMICS OY

1.85M€ | Lider

COFOCYL

197.62K€ | Participante

INDUSTRIAS DE NUTRICION ANIM...

198.51K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

TRIOP TRIOP: an intraoperative probe to assess tumor margins and r... 75K€ Cerrado

Olfactomics Bringing Surgery to the 21st Century Feasibility Verificati... 71K€ Cerrado

PICTURE Patient Information Combined for the Assessment of Specific... 3M€ Cerrado

OMIS Feasibility study on Opto Magnetic Imaging Spectroscopy for... 71K€ Cerrado

CerISMA Cerenkov Imaging for Surgical Margin Assessment 2M€ Cerrado

SURVIVE Integrating cancer detection and SURgery Via molecular Imagi... 2M€ Cerrado

Duración del proyecto: 45 meses Fecha Inicio: 2019-03-05
Fecha Fin: 2022-12-31

Líder del proyecto

OLFACTOMICS OY No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 3M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Currently, cancer tumor removal operation is based on preoperative imaging and postoperative pathological examination. There is a strong global trend towards more tissue-sparing and minimally invasive surgery. If all cancer is not removed in the operation, a reoperation is needed, leading to additional costs, impaired cost-effectiveness and impaired quality of life of the patient. The rate of incomplete removal of a tumor ranges from 10-60%. The breakthrough innovative Olfactomics device allows the surgeon to analyze the operated tissue in real-time during cancer surgery leading to optimal tissue removal without compromising the workflow of the operation and facilitating the use of existing instrumentation. The solution is based on noninvasive, real-time analysis of surgical smoke. The reduced reoperation rate results in significant benefits for the patient, surgeon, hospital and society. The market potential is high. Easily reachable market for the breast cancer surgery is 850M€ and market for other applicable specialties (such as prostate cancer, skin cancer, and intestinal surgery) is over 2,000M€. Olfactomics Oy is a Finnish university-based spinoff company founded in 2015 to commercialize the results of over 10 years of clinical and technical research. The team consists of 13 specialists in surgery, medical technology, software, data analysis, financials and law. The team has excellent connections in the international healthcare industry and sensor technology industry. The technology is currently at TRL 7. The first commercial product for research use will be launched in 2019. This project will focus on scale-up to Olfactomics medical device on breast cancer surgery. The impacts by 2027 include: +3,000 Olfactomics devices sold; +300,000 Olfactomics breast cancer surgeries performed, +70,000 women saved from reoperation, +900M€ costs savings in health care, +100M€ revenue and +200 direct workplaces generated. Scale-up to several surgical areas will follow.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores